background
allerg
reaction
hymenoptera
insect
sting
remain
major
global
clinic
problem
although
effect
parenter
desensit
regimen
requir
use
costli
venom
extract
requir
frequent
visit
extend
period
time
might
provid
similar
benefit
allergi
desensit
method
random
control
phase
trial
undertaken
adult
histori
rapidonset
system
allerg
reaction
honeybe
sting
posit
specif
ige
level
evalu
safeti
efficaci
honeybe
venom
immunotherapi
hbvit
combin
advax
adjuv
venom
immunotherapi
vit
administ
monthli
month
achiev
mainten
dose
result
advaxadjuv
hbvit
well
toler
around
week
vit
specif
igg
respons
peak
group
increas
earlier
peak
higher
better
maintain
end
studi
advaxadjuv
arm
sever
differ
pattern
serolog
respons
vit
seen
subject
domin
igg
respons
combin
igg
igg
respons
exclus
igg
respons
subject
specif
ige
level
increas
induct
phase
decreas
wherea
other
specif
ige
level
progress
decreas
start
vit
conclus
advax
adjuv
favor
enhanc
immunogen
hbvit
earli
prolong
switch
specif
igg
product
abil
advax
adjuv
enhanc
vit
efficaci
warrant
studi
j
allergi
clin
immunol
key
word
hymenoptera
anaphylaxi
immunotherapi
igg
inulin
adjuv
allergi
anaphylact
reaction
hymenoptera
insect
sting
major
clinic
problem
mani
part
world
although
venom
immunotherapi
vit
effect
prevent
lifethreaten
reaction
futur
sting
caus
sever
even
although
rare
lifethreaten
reaction
also
less
effect
honeybe
vespula
speci
wasp
sting
myrmecia
pilosula
jack
jumper
ant
sting
second
common
caus
sting
anaphylaxi
south
australia
furthermor
cours
honeybe
venom
immunotherapi
hbvit
immedi
system
reaction
includ
mild
anaphylact
reaction
common
larg
us
european
studi
rate
system
reaction
subject
undergo
hbvit
similar
system
reaction
saw
vit
jumper
ant
venom
rate
comparison
lower
rate
system
reaction
rate
vit
vespid
venom
northern
hemispher
studi
median
time
taken
achiev
mainten
dose
hbvit
week
us
studi
outpati
vit
compar
experi
week
cluster
regimen
attempt
acceler
achiev
mainten
dose
use
ultrarush
inpati
regimen
variabl
effect
reaction
rate
interpret
confound
comparison
nonrandom
gener
noncontemporan
studi
suggest
reaction
rate
vit
even
greater
regimen
reaction
hbvit
gener
sever
frequent
vespid
vit
minor
subject
receiv
hbvit
achiev
mainten
dose
hbvit
proport
quot
retrospect
studi
lockey
et
al
experi
typic
rang
leav
subgroup
suscept
recurr
stinginduc
anaphylaxi
even
subject
establish
dose
regimen
literatur
evid
high
probabl
protect
stinginduc
anaphylaxi
question
remain
regard
optim
durat
vit
propens
vit
ceas
suscept
stinginduc
anaphylaxi
recur
sting
updat
us
practic
paramet
suggest
vit
discontinu
year
lowrisk
patient
patient
vit
less
chanc
system
reaction
subsequ
sting
wherea
extend
indefinit
treatment
suggest
highrisk
patient
patient
greater
chanc
relaps
limit
evid
abolit
detect
specif
ige
respons
venom
marker
protect
stinginduc
anaphylaxi
studi
golden
group
minor
subject
lost
skin
test
reactiv
venom
year
vit
approxim
year
vit
neg
skin
test
respons
wherea
respons
becam
neg
year
followup
thu
one
third
subject
might
either
need
indefinit
continu
vit
continu
carri
autom
adrenalin
syring
australia
commerci
avail
honeybe
venom
gener
use
albey
bee
venom
api
mellifera
hollistersti
spokan
wash
solubl
extract
sever
european
studi
administ
hymenoptera
venom
alum
adjuv
although
alum
reduc
local
advers
reaction
vit
presum
bind
delay
allergen
releas
shown
acceler
desensit
reduc
requir
venom
dose
alum
also
potenti
disadvantag
allergi
therapi
given
propens
enhanc
ige
product
eosinophilia
opposit
desir
ideal
allergi
immunotherapi
adjuv
advax
vaxin
pti
ltd
adelaid
australia
new
adjuv
deriv
natur
plantbas
polysaccharid
delta
inulin
develop
nation
institut
health
adjuv
develop
program
advax
shown
provid
enhanc
vaccin
immunogen
antigen
spare
low
reactogen
drive
strong
h
respons
might
help
suppress
excess
h
bia
allerg
patient
notabl
formul
advax
vaccin
sever
acut
respiratori
syndrom
sar
abl
suppress
eosinophil
lung
patholog
sar
coronaviru
infect
wherea
problem
aggrav
formul
sar
vaccin
alum
adjuv
advax
adjuv
shown
safe
effect
human
vaccin
trial
sought
therefor
test
hypothesi
advax
adjuv
would
enhanc
effect
hbvit
healthi
adult
histori
rapidonset
system
allerg
reaction
honeybe
venom
posit
test
result
serum
specif
ige
kul
thermo
fisher
cap
recruit
random
ratio
cluster
semirush
hbvitadminist
mean
subcutan
inject
either
standard
honeybe
venom
immunotherapi
shbvit
combin
advax
adjuv
ahbvit
fig
studi
approv
human
ethic
committe
flinder
medic
centr
royal
adelaid
hospit
start
may
last
particip
complet
march
subsequ
ethic
approv
obtain
recal
particip
obtain
addit
blood
sampl
measur
specif
ige
igg
level
year
particip
complet
activ
trial
therapi
twentyseven
adult
subject
age
year
histori
rapidonset
system
allerg
reaction
bee
sting
posit
specif
ige
level
kul
thermo
fisher
cap
test
enrol
subject
exclud
previous
undergon
hbvit
baselin
mast
cell
tryptas
mct
level
greater
mgl
pregnant
lactat
women
childbear
potenti
unless
use
reliabl
appropri
contracept
method
receiv
concurr
system
immunosuppress
therapi
histori
intraven
drug
alcohol
abus
particip
anoth
clinic
trial
investig
agent
within
day
preced
initi
treatment
seriou
medic
social
mental
condit
opinion
investig
would
detriment
subject
studi
none
subject
treatment
bblocker
angiotensinconvert
enzym
inhibitor
albey
bee
venom
reconstitut
diluent
albumin
salin
phenol
preserv
instruct
manufactur
store
use
within
expir
date
accord
manufactur
recommend
advax
adjuv
delta
inulin
mgml
without
preserv
singledos
vial
mix
honeybe
venom
asept
condit
within
hour
use
schedul
inject
administ
deep
subcutan
inject
upper
outer
arm
abdomin
skin
depend
patient
prefer
accord
schedul
tabl
articl
onlin
repositori
wwwjacionlineorg
advaxhoneybe
venom
mixtur
opaqu
standard
honeybe
venom
clear
administr
blind
impract
therefor
inject
administ
nurs
staff
awar
group
alloc
wherea
patient
medic
investig
remain
blind
studi
group
puls
blood
pressur
respiratori
rate
oxygen
satur
skin
statu
gener
inject
site
record
minut
inject
leav
clinic
minut
last
inject
attend
immedi
symptomat
clinic
signific
reaction
defin
follow
immedi
system
hypersensit
reaction
classifi
grade
specif
mild
moder
sever
accord
criteria
brown
base
evid
relationship
particular
manifest
progress
hypotens
hypoxia
excess
local
reaction
inject
site
classifi
mild
local
swell
mm
moder
local
swell
mm
sever
local
swell
mm
andor
extend
across
joint
andor
caus
signific
disabl
system
reaction
immedi
hypersensit
reaction
classifi
mild
interf
significantli
usual
activ
requir
treatment
oral
antihistamin
simpl
mild
analges
moder
fever
shortterm
interfer
usual
activ
meet
criteria
sever
sever
fever
reaction
requir
hospit
treatment
admiss
consist
usual
clinic
practic
schedul
vari
follow
excess
local
reaction
last
dose
repeat
reaction
extend
beyond
joint
elbow
last
toler
dose
given
mild
gener
allerg
reaction
discret
investig
dose
repeat
reduc
last
toler
dose
signific
gener
reaction
dose
reduc
last
toler
dose
discret
investig
increment
reduc
safeti
blood
test
includ
full
blood
estim
liver
function
test
measur
serum
mct
urea
electrolyt
creactiv
protein
crp
complement
antinuclear
antibodi
rheumatoid
factor
valu
assay
nation
associ
test
author
australiacertifi
commerci
patholog
servic
sa
patholog
adelaid
australia
collect
commenc
studi
week
vit
full
blood
estim
liver
function
test
urea
electrolyt
measur
mainten
reach
around
week
month
mainten
therapi
blood
collect
assess
specif
ige
igg
level
perform
immedi
vit
commenc
week
start
vit
reach
mainten
thereaft
everi
third
month
end
studi
followup
period
specif
ige
igg
level
measur
use
immunocap
phadia
assay
thermo
scientif
uppsala
sweden
sa
patholog
accord
manufactur
instruct
addit
detail
method
use
includ
articl
onlin
repositori
wwwjacionlineorg
addit
specif
total
igg
igg
igg
level
measur
mean
elisa
elisa
plate
coat
ml
albey
bee
venom
mgml
overnight
wash
block
hour
bsa
pb
serum
sampl
dilut
block
buffer
ad
duplic
well
incub
room
temperatur
hour
wash
next
biotinyl
antihuman
total
igg
antihuman
igg
igg
ad
well
incub
hour
follow
wash
addit
horseradish
peroxidaseconjug
streptavidin
hour
plate
thoroughli
wash
tetramethylbenzidin
substrat
ad
minut
reaction
stop
ml
moll
phosphor
acid
od
well
read
nm
od
spectrophotomet
plate
reader
versamax
molecular
devic
sunnyval
calif
analyz
softmax
pro
softwar
venom
skin
test
perform
baselin
week
month
skin
test
perform
antihistamin
medic
includ
neg
control
normal
pb
dilut
venom
albey
bee
venom
extract
mgml
inject
dermi
undersid
upper
forearm
posit
control
histamin
acid
phosphat
mgml
skin
prick
test
otherwis
skin
test
perform
intraderm
rout
skin
test
read
minut
posit
test
result
record
wheal
mm
diamet
greater
elicit
neg
control
primari
prespecifi
end
point
follow
number
subject
group
reach
mainten
number
grade
object
system
immedi
hypersensit
reaction
group
chang
venom
skin
test
respons
group
secondari
end
point
includ
follow
chang
baselin
end
point
vitro
measur
specif
ige
specif
igg
number
size
local
advers
reaction
per
subject
care
subject
end
studi
base
publish
studi
review
golden
polici
unit
continu
mainten
vit
least
year
subject
immedi
system
reaction
bee
sting
indefinit
basi
extrem
lifethreaten
reaction
typic
major
hypotens
reaction
combin
advax
adjuv
licens
product
month
mainten
therapi
subject
exit
blind
random
therapi
offer
convent
vit
immunotherapi
mgmo
year
indefinit
depend
sever
past
sting
reaction
patient
withdrew
chang
work
circumst
reach
mainten
dose
offer
opportun
complet
convent
vit
treatment
communitybas
set
routin
sting
challeng
end
trial
perform
lack
resourc
safeti
efficaci
analys
perform
subject
commenc
vit
data
analyz
use
stata
version
statacorp
colleg
station
tex
graphpad
prism
version
graphpad
softwar
la
jolla
calif
softwar
mean
ci
specif
ige
level
specif
igg
level
specif
igespecif
igg
ratio
across
time
shown
outcom
analyz
use
mixedeffect
model
includ
random
intercept
subject
account
withinsubject
correl
across
time
model
includ
fix
effect
intervent
group
time
categor
variabl
visit
age
categori
greater
less
median
age
sex
also
includ
addit
term
baselin
valu
increas
precis
avoid
regress
mean
effect
assess
whether
chang
mean
across
time
vari
differ
group
model
includ
group
time
interact
term
perform
global
test
signific
base
df
time
point
sensit
analys
also
assess
whether
effect
sex
vari
across
time
includ
sex
time
interact
term
assumpt
mix
effect
model
confirm
assess
level
error
level
individu
level
residu
differ
mean
time
point
consid
signific
global
test
signific
p
mean
individu
time
point
signific
p
valu
less
adjust
comparison
bonferroni
adjust
data
clinic
demograph
characterist
assess
normal
present
mean
sd
normal
distribut
variabl
median
rang
nonnorm
distribut
variabl
twentyseven
subject
met
select
criteria
subject
exclud
consent
particip
trial
random
receiv
shbvit
random
receiv
ahbvit
fig
low
enrol
rate
due
mani
elig
subject
instead
opt
therapi
use
ultrarush
regimen
offer
center
none
patient
receiv
treatment
bblocker
angiotensinconvert
enzym
inhibitor
one
subject
alloc
ahbvit
group
withdrew
alter
work
commit
start
treatment
includ
analys
baselin
characterist
remain
subject
shown
tabl
slightli
greater
proport
subject
histori
hypotens
anaphylaxi
bee
sting
random
shbvit
group
j
allergi
clin
immunol
volum
number
compar
ahbvit
group
three
subject
shbvit
group
baselin
serum
mct
level
rang
mgl
wherea
subject
ahbvit
group
margin
increas
baselin
mct
level
mgl
none
subject
clinic
featur
mast
cell
disord
subject
increas
mct
level
histori
trial
anaphylaxi
hypotens
respons
bee
sting
one
subject
increas
mct
level
shbvit
group
stung
bee
separ
occas
trial
local
reaction
anoth
subject
increas
mct
level
shbvit
group
toler
wasp
sting
trial
third
subject
shbvit
group
subject
ahbvit
group
increas
mct
level
experi
sting
trial
mean
total
specif
ige
level
smoke
histori
comorbid
histori
allerg
disord
greater
andor
frequent
baselin
ahbvit
group
statist
signific
differ
group
age
grade
worst
prior
bee
sting
reaction
mct
level
total
ige
level
specif
ige
level
specif
igg
level
baselin
report
nonstinginduc
anaphylaxi
repres
reaction
penicillin
particip
sulfit
particip
ahbvit
group
seafood
particip
shbvit
group
blood
test
taken
week
reach
mainten
phase
studi
complet
reveal
clinic
signific
laboratori
abnorm
class
like
relat
vit
particular
signific
differ
inflammatori
marker
includ
crp
see
fig
articl
onlin
repositori
wwwjacionlineorg
total
white
cell
count
wcc
see
fig
articl
onlin
repositori
wwwjacionlin
org
time
group
consist
previou
report
advax
essenti
noninflammatori
inulin
particl
activ
altern
complement
pathway
subject
ahbvit
group
receiv
approxim
dose
total
approxim
g
delta
inulin
studi
serum
level
complement
factor
assess
detect
complement
chang
signific
differ
serum
see
fig
mct
level
measur
marker
mast
cell
activ
signific
differ
mct
level
studi
group
overal
trend
mct
level
decreas
time
group
see
fig
articl
onlin
repositori
wwwjacionlineorg
similar
report
decreas
baselin
serum
mct
level
per
year
mean
year
vit
report
advers
reaction
common
group
predominantli
made
local
see
secondari
end
point
gener
allerg
reaction
occur
observ
period
inject
see
primari
end
point
advers
event
classifi
investig
like
relat
advax
adjuv
small
nontend
subcutan
nodul
vit
inject
site
subject
regress
week
month
overal
ahbvit
shbvit
assess
studi
investig
safe
toler
number
subject
reach
mainten
two
subject
ahbvit
group
stay
trial
long
enough
reach
monthli
mainten
therapi
chang
work
commit
lead
withdraw
week
subject
ahbvit
group
reach
monthli
mainten
subject
later
withdrew
vari
period
treatment
chang
employ
circumst
shbvit
group
singl
subject
withdrawn
repeat
immedi
system
reaction
occas
reach
mainten
dose
despit
interven
reduc
dose
unsuccess
attempt
get
around
issu
subject
shbvit
group
reach
monthli
mainten
number
system
immedi
hypersensit
reaction
group
ahbvit
group
subject
experienc
total
grade
reaction
grade
reaction
none
grade
reaction
shbvit
group
subject
experienc
total
grade
reaction
grade
reaction
subject
withdrawn
second
hypotens
anaphylaxi
grade
reaction
see
tabl
articl
onlin
repositori
wwwjacionlineorg
subject
recov
promptli
fulli
reaction
standard
treatment
biphas
reaction
observ
none
subject
increas
baselin
mct
level
object
system
reaction
hbvit
venom
skin
test
group
group
venom
skin
test
sensit
decreas
throughout
cours
vit
evidenc
increas
concentr
honeybe
venom
requir
elicit
posit
respons
week
month
mainten
therapi
see
fig
tabl
articl
onlin
repositori
wwwjacionlineorg
statist
differ
venom
skin
test
sensit
score
group
time
point
honey
bee
venomspecif
ige
respons
studi
entri
nonsignific
trend
toward
greater
specif
ige
level
ahbvit
group
substanti
overlap
level
group
group
overal
increas
specif
ige
level
commenc
therapi
reach
peak
around
week
progress
decreas
thereaft
fig
specif
ige
level
got
back
baselin
valu
around
week
group
progress
decreas
end
studi
analyz
anova
differ
group
time
sex
age
reduct
specif
ige
level
signific
group
time
p
significantli
differ
group
fig
effect
specif
ige
respons
sex
see
fig
articl
onlin
repositori
www
jacionlineorg
subject
age
see
fig
articl
onlin
repositori
wwwjacionlineorg
examin
specif
ige
respons
individu
subject
see
fig
articl
onlin
repositori
wwwjacionlineorg
reveal
differ
pattern
pattern
show
immedi
decreas
specif
ige
commenc
vit
wherea
anoth
pattern
show
larg
increas
specif
ige
level
week
vit
initi
specif
ige
decreas
baselin
level
month
mainten
vit
approxim
half
subject
group
fell
pattern
subject
multipl
sting
short
space
time
eg
subject
major
increas
specif
ige
level
immedi
suggest
sting
caus
either
prime
boost
underli
ige
memori
bcell
respons
see
fig
specif
igg
respons
igg
block
antibodi
suggest
play
major
role
prevent
reaction
earli
vit
specif
ige
level
still
high
wherea
block
antibodi
may
progress
less
import
specif
ige
level
decreas
time
henc
one
measur
earli
efficaci
vit
might
induct
specif
igg
thought
domin
block
subclass
studi
entri
mean
level
specif
igg
significantli
differ
group
fig
low
subject
bar
subject
ahbvit
group
subject
see
fig
exclud
possibl
high
baselin
igg
result
subject
due
interf
antimous
antibodi
test
whether
specif
igg
activ
could
adsorb
ad
mous
sera
bee
venom
solubl
phase
assay
specif
igg
activ
adsorb
bee
venom
normal
mous
sera
data
shown
confirm
subject
high
specif
igg
level
start
vit
vit
commenc
specif
igg
level
rapidli
diverg
shbvit
ahbvit
group
increas
rapidli
reach
higher
peak
ahbvit
group
higher
specif
igg
level
ahbvit
group
alreadi
seen
earli
week
extent
differ
increas
vit
progress
fig
greater
specif
igg
level
ahbvit
group
continu
month
month
cessat
studi
intervent
contrast
specif
igg
level
return
back
toward
baselin
level
mani
subject
shbvit
group
year
despit
ongo
vit
overal
male
subject
significantli
greater
specif
igg
respons
femal
subject
male
subject
vs
femal
subject
p
sensit
analys
signific
differ
chang
mean
specif
igg
advax
adjuv
work
well
male
femal
subject
compens
lower
respons
femal
subject
vit
end
studi
specif
igg
level
femal
subject
ahbvit
group
greater
male
subject
shbvit
group
see
fig
specif
igg
subclass
respons
igg
subtyp
includ
igg
also
play
role
block
antibodi
level
specif
total
igg
individu
subtyp
igg
igg
measur
use
elisa
mani
subject
show
increas
specif
igg
level
parallel
specif
igg
respons
peak
week
induct
phase
follow
plateau
throughout
mainten
phase
fig
specif
igg
respons
specif
igg
respons
higher
ahbvit
group
major
subject
shbvit
group
small
increas
specif
igg
level
major
higher
specif
igg
igg
respons
subject
subject
see
fig
exclus
igg
respons
hbvit
contrast
major
subject
ahbvit
group
higher
specif
igg
igg
respons
see
fig
subject
ahbvit
group
specif
igg
respons
initi
greater
specif
igg
respons
month
subject
still
margin
higher
specif
igg
igg
level
henc
month
subject
ahbvit
group
higher
specif
igg
igg
level
level
total
specif
igg
sum
igg
subclass
show
similar
pattern
specif
igg
igg
level
fig
total
specif
igg
elisa
note
high
background
even
baselin
rel
specif
igg
igg
elisa
nevertheless
specif
total
igg
level
increas
subject
commenc
vit
slowli
wane
year
vit
administr
interestingli
specif
total
igg
level
subject
remain
increas
baselin
valu
even
specif
igg
igg
level
rel
low
undetect
suggest
specif
total
igg
elisa
might
sensit
igg
igg
assay
see
fig
longterm
followup
specif
ige
igg
measur
studi
complet
year
particip
complet
activ
studi
treatment
revert
ongo
standard
hbvit
ceas
hbvit
altogeth
ethic
permiss
obtain
invit
studi
particip
provid
addit
blood
sampl
assess
longterm
specif
ige
igg
respons
given
long
durat
sinc
end
studi
blood
sampl
abl
obtain
origin
particip
shbvit
group
ahbvit
group
group
show
reduct
specif
ige
level
level
measur
end
studi
increas
specif
igg
seen
activ
vit
ahbvit
group
larg
attenu
time
fig
suggest
ongo
inclus
advax
mainten
vit
may
necessari
maintain
high
specif
igg
level
longterm
local
advers
reaction
local
reaction
expect
common
statist
signific
group
report
subject
ahbvit
group
upper
arm
start
hour
inject
persist
hour
hour
inject
urticaria
lip
angioedema
wheez
assess
local
medic
practition
show
desatur
hypotens
recov
promptli
intramuscular
adrenalin
except
local
swell
forearm
persist
anoth
hour
subject
went
receiv
dose
vit
without
major
incid
incident
honeybe
sting
reaction
subject
encourag
minim
sting
risk
studi
total
bee
sting
report
studi
involv
subject
ahbvit
group
see
fig
subject
shbvit
group
see
fig
one
subject
beekeep
shbvit
group
experienc
earli
subject
manifest
consist
grade
reaction
bee
sting
occas
involv
total
sting
sting
subject
toler
medic
attent
sought
sting
particip
although
subject
equip
adrenalin
autoinjector
instruct
use
gener
reaction
subject
use
devic
subject
highest
baselin
mct
level
mgl
report
bee
sting
local
reaction
anoth
subject
increas
baselin
mct
level
toler
presum
wasp
sting
advers
reaction
hymenoptera
vit
proven
efficaci
sting
insect
domin
europ
north
america
honeybe
jumper
jack
ant
allergi
australia
howev
problem
hbvit
remain
includ
signific
advers
reaction
rate
need
frequent
inject
visit
failur
subject
achiev
mainten
possibl
recurr
sensit
cessat
vit
given
shortcom
adjuv
abl
acceler
desensit
reduc
vit
dose
frequenc
andor
prolong
durat
protect
could
broad
util
allergen
immunotherapi
ideal
adjuv
would
help
drive
immun
respons
allergen
away
h
bia
therebi
help
reduc
eosinophilia
ige
product
inulin
plantbas
fructan
polym
compris
linear
chain
fructos
unit
connect
b
glycosid
bond
cap
reduc
end
ad
glucopyranosid
ring
crystal
specif
semicrystallin
form
delta
inulin
inulin
chain
associ
hydrogen
bond
creat
order
antiparallel
helic
form
lamellar
sheet
semicrystallin
state
refer
delta
inulin
advax
adjuv
inulin
acquir
uniqu
immunolog
properti
includ
abil
act
potent
vaccin
adjuv
advax
adjuv
shown
boost
humor
cellular
immun
enhanc
vaccinemedi
protect
across
wide
varieti
viral
bacteri
protozoan
antigen
multipl
speci
includ
human
subject
first
studi
assess
human
safeti
efficaci
advax
combin
allergen
use
immunotherapi
studi
confirm
advax
adjuv
safe
well
toler
even
particip
receiv
approxim
consecut
dose
year
local
reaction
common
group
throughout
studi
expect
nonsignific
trend
toward
local
reaction
predominantli
concentr
mild
categori
adjuv
group
signific
reduct
venom
skin
test
reactiv
group
vit
although
proviso
skin
test
might
weak
correl
clinic
protect
sting
challeng
consid
gold
standard
outcom
measur
vit
perform
studi
resourc
limit
howev
studi
current
underway
advax
adjuv
ant
sting
allergi
vit
ant
sting
challeng
perform
assess
efficaci
help
address
issu
immunotherapi
sting
insect
anaphylaxi
thought
work
sever
mechan
includ
product
igg
block
antibodi
bind
allergen
reduc
effector
cell
function
mast
cell
basophil
eosinophil
lead
reduc
h
activ
attenu
ige
product
keep
concept
toler
beekeep
shown
increas
level
specif
igg
togeth
specif
ige
henc
induct
specif
igg
consid
import
surrog
marker
effect
allergen
immunotherapi
notabl
advax
adjuv
markedli
increas
specif
igg
respons
compar
shbvit
group
specif
igg
level
stay
high
end
treatment
period
contrast
shbvit
group
peak
specif
igg
level
lower
rapidli
wane
back
toward
baselin
level
even
ongo
mainten
therapi
consist
studi
show
increas
baselin
specif
igg
level
year
standard
vit
reduct
specif
ige
level
remain
unclear
whether
increas
specif
igg
level
decreas
specif
ige
level
relev
vit
clinic
efficaci
might
reflect
previou
difficulti
induc
suffici
high
block
igg
problem
studi
suggest
solv
incorpor
advax
adjuv
vit
clinic
respons
grass
pollen
immunotherapi
function
assay
igg
associ
inhibitori
activ
inhibit
igeallergen
interact
inhibit
igefacilit
allergen
bind
correl
better
clinic
outcom
immunoreact
igg
level
henc
interest
futur
studi
advaxadjuv
vit
also
includ
function
assay
igg
associ
inhibitori
activ
interestingli
high
specif
igg
level
attenu
significantli
ahbvit
particip
survey
year
complet
studi
treatment
suggest
inclus
advax
adjuv
ongo
vit
might
necessari
sustain
high
specif
igg
level
long
term
recal
ahbvit
particip
evid
even
attenu
specif
ige
level
time
studi
complet
fig
continu
longterm
decreas
specif
ige
level
might
reflect
natur
death
time
igeproduc
plasmablast
togeth
failur
replac
deplet
memori
bcell
compart
requir
replenish
ige
plasmablast
effect
regulatori
cell
prevent
gener
igeproduc
b
cell
futur
would
interest
test
whether
function
assay
serum
inhibitori
activ
greater
subject
receiv
advax
also
directli
measur
frequenc
specif
igeand
igg
posit
memori
b
cell
throughout
cours
vit
difficulti
design
clinic
vit
studi
select
assay
use
potenti
ait
respons
biomark
topic
recent
review
work
parti
european
academi
allergi
clinic
immunolog
allergenspecif
regulatori
cell
character
secret
play
role
vit
drive
product
igg
posit
regulatori
b
cell
exampl
previou
studi
nonallerg
beekeep
show
presenc
bee
venomspecif
igg
posit
regulatori
b
cell
regulatori
b
cell
also
found
increas
allerg
subject
vit
henc
higher
specif
igg
level
ahbvit
group
might
reflect
effect
advax
adjuv
expans
regulatori
cell
regulatori
b
cell
make
igg
import
question
address
futur
studi
interestingli
male
subject
significantli
greater
specif
igg
respons
nonsignific
trend
toward
lower
specif
ige
level
vit
femal
subject
consist
femal
subject
postmenarch
h
immun
system
make
prone
allergi
howev
year
vit
femal
subject
group
reduc
specif
ige
level
indic
vit
effect
irrespect
sex
role
nonigg
subclass
block
antibodi
patient
venom
allergi
remain
unclear
antigen
specif
rather
igg
subclass
shown
domin
factor
determin
abil
block
allergendepend
ige
activ
differ
igg
subclass
allergen
specif
produc
test
specif
igg
level
also
greater
ahbvit
group
specif
igg
behav
similarli
specif
igg
peak
induct
phase
plateau
mainten
phase
ahbvit
group
slowli
decreas
shbvit
group
howev
examin
time
trend
specif
igg
igg
individu
subject
reveal
complex
pattern
subject
make
domin
specif
igg
respons
make
combin
specif
igg
igg
respons
make
exclus
specif
igg
respons
notabl
subject
good
specif
igg
respons
specif
igg
respons
subject
singl
bee
sting
around
month
respect
neither
system
reaction
igg
subclass
differ
might
influenc
vit
clinic
outcom
import
area
futur
research
although
specif
ige
level
differ
significantli
group
differ
pattern
ige
respons
seen
one
pattern
ige
respons
specif
ige
level
start
decreas
directli
commenc
vit
initi
increas
ige
level
induct
phase
vit
pattern
respons
rel
larg
increas
specif
ige
level
week
vit
initi
ige
level
decreas
previt
level
least
month
mainten
vit
thereaft
rapidli
decreas
approxim
half
subject
shbvit
ahbvit
group
fell
pattern
interestingli
major
subject
experienc
system
immedi
hypersensit
reaction
vit
group
initi
increas
ige
surpris
result
might
expect
system
immedi
hypersensit
reaction
would
exacerb
sharp
increas
specif
ige
level
vit
subject
specul
lack
reaction
group
despit
increas
ige
level
might
parallel
increas
subject
specif
igg
igg
might
compens
increas
ige
minor
subject
report
sting
enter
studi
seriou
system
reaction
none
requir
adrenalin
therapi
suggest
vit
effect
subject
interestingli
subject
shbvit
group
subject
ahbvit
group
subject
sharp
increas
specif
ige
level
respons
seri
bee
sting
suggest
possibl
bee
sting
restimul
ige
product
despit
ongo
vit
fresh
sting
might
induc
differ
immun
respons
bee
venom
use
vit
clear
might
reflect
addit
labil
vasoact
substanc
enzym
contain
fresh
venom
longer
present
preserv
bee
venom
summari
result
support
potenti
benefit
advax
adjuv
vit
consist
benefit
previous
seen
advax
adjuv
infecti
diseas
vaccin
although
directli
assess
studi
increas
specif
igg
level
advax
adjuv
group
earli
induct
phase
low
dose
allergen
administ
suggest
advax
adjuv
might
use
venom
dosespar
abil
particularli
earli
stage
vit
importantli
first
time
human
subject
studi
confirm
safeti
toler
vit
combin
advax
adjuv
henc
advax
adjuv
promis
candid
vit
ongo
studi
assess
abil
provid
antigenspar
effect
ant
venom
allergi
therapi
hbvit
protocol
ahbvit
group
shown
tabl
shbvit
group
receiv
protocol
without
addit
advax
adjuv
laboratori
assess
treatment
safeti
crp
level
total
wcc
assess
marker
inflamm
signific
chang
crp
level
fig
wcc
fig
across
time
group
data
shown
mean
se
group
minimum
maximum
normal
rang
shown
horizont
black
line
similarli
complement
factor
measur
marker
complement
pathway
dysregul
signific
chang
fig
fig
level
across
time
studi
group
margin
greater
level
seen
group
month
time
point
like
caus
assay
calibr
drift
rather
true
chang
serum
mct
level
measur
marker
mast
cell
activ
signific
chang
mct
level
across
time
studi
group
fig
anyth
trend
mct
level
reduc
time
studi
group
vit
progress
steadi
increas
group
number
respond
time
point
vit
week
month
month
toler
greater
dose
venom
requir
elicit
posit
venom
skin
test
respons
subject
baselin
fig
although
trend
toward
increas
frequenc
respond
ahbvit
group
time
point
differ
group
statist
signific
p
anova
overal
group
manyfold
greater
dose
venom
baselin
requir
posit
skin
reaction
end
studi
microgram
per
millilit
log
tabl
adjust
margin
mean
across
time
specif
ige
age
categori
fig
sex
fig
respect
show
signific
overal
differ
variat
mean
specif
ige
level
across
time
intervent
group
x
df
p
peak
visit
ahbvit
group
follow
rapid
decreas
compar
gradual
decreas
across
time
shbvit
group
differ
mean
visit
borderlin
signific
p
signific
differ
time
point
adjust
multipl
comparison
signific
differ
adjust
mean
specif
ige
level
age
less
year
age
year
vs
p
male
femal
subject
vs
p
sensit
analys
also
differ
chang
mean
specif
ige
level
across
time
sex
p
error
bar
repres
ci
adjust
margin
mean
specif
igg
level
across
time
age
assess
use
mixedeffect
model
adjust
age
group
sex
time
baselin
valu
mean
significantli
differ
overal
across
time
effect
seen
age
fig
signific
effect
sex
women
lower
specif
igg
respons
men
fig
relationship
specif
total
igg
igg
igg
ige
level
time
subject
receiv
standard
adjuv
vit
specif
total
igg
igg
igg
level
measur
mean
elisa
specif
ige
level
use
immunocap
assay
base
ige
respons
differ
pattern
emerg
subject
receiv
vit
group
pattern
show
almost
immedi
decreas
specif
ige
level
commenc
vit
absenc
initi
increas
ige
level
fig
group
pattern
show
larg
increas
specif
ige
level
week
initi
vit
ige
decreas
previt
level
month
mainten
vit
approxim
half
subject
shbvit
ahbvit
group
fell
categori
fig
pink
arrow
repres
system
immedi
hypersensit
reaction
vit
black
arrow
indic
incident
bee
sting
none
result
system
reaction
surprisingli
major
subject
experienc
system
immedi
hypersensit
reaction
vit
concentr
pattern
group
although
analysi
baselin
data
show
mean
specif
igg
level
baselin
greater
subject
pattern
mean
specif
igg
sd
versu
pattern
mean
specif
igg
sd
differ
reach
statist
signific
p
mannwhitney
test
notic
subject
multipl
sting
short
space
time
eg
subject
major
increas
specif
ige
level
immedi
suggest
repeat
prime
boost
ige
bcell
memori
respons
specif
total
igg
elisa
assay
note
high
background
rel
specif
igg
igg
elisa
reason
clear
nevertheless
specif
total
igg
level
increas
subject
commenc
vit
stay
high
slowli
wane
year
vit
interestingli
specif
total
igg
level
subject
remain
increas
baselin
valu
even
specif
igg
igg
level
low
undetect
suggest
specif
total
igg
assay
might
much
sensit
either
igg
igg
assay
alon
interestingli
subject
greatest
specif
total
igg
level
appear
greatest
suppress
ige
level
time
exampl
wane
specif
total
igg
level
subject
recent
followup
associ
upward
spike
specif
ige
level
similarli
subject
minim
increas
specif
total
igg
level
vit
exhibit
major
spike
ige
level
standard
hbvit
individu
subject
serolog
respons
data
shown
specif
total
igg
igg
igg
level
measur
mean
elisa
specif
ige
level
measur
use
immunocap
assay
fig
advaxadjuv
hbvit
individu
subject
serolog
respons
data
shown
specif
total
igg
igg
igg
level
measur
mean
elisa
specif
ige
level
measur
use
immunocap
assay
